MCID: PRS031
MIFTS: 24

Prostate Carcinoma in Situ

Categories: Cancer diseases, Reproductive diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Prostate Carcinoma in Situ

MalaCards integrated aliases for Prostate Carcinoma in Situ:

Name: Prostate Carcinoma in Situ 12 14
Carcinoma in Situ of Prostate 12 69
Grade Iii Pin 12
Pin Iii 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8634
ICD10 33 D07.5
ICD9CM 35 233.4
NCIt 47 C3642
SNOMED-CT 64 128640002 92691004
UMLS 69 C0154088

Summaries for Prostate Carcinoma in Situ

MalaCards based summary : Prostate Carcinoma in Situ, also known as carcinoma in situ of prostate, is related to prostatitis and duodenitis. An important gene associated with Prostate Carcinoma in Situ is LPP (LIM Domain Containing Preferred Translocation Partner In Lipoma). The drugs Toremifene and Selenium have been mentioned in the context of this disorder. Affiliated tissues include prostate, breast and bone, and related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Prostate Carcinoma in Situ

Diseases in the Prostate Cancer family:

Prostate Cancer 1 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 13
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 7
Prostate Cancer, Hereditary, 2 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 9 Prostate Cancer, Hereditary, 15
Prostate Carcinoma in Situ

Diseases related to Prostate Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 prostatitis 9.7
2 duodenitis 7.5 ALDOA GH2 GPSM2 LPP SLURP1 TMPRSS15

Comorbidity relations with Prostate Carcinoma in Situ via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostate Cancer Prostatic Hypertrophy

Symptoms & Phenotypes for Prostate Carcinoma in Situ

GenomeRNAi Phenotypes related to Prostate Carcinoma in Situ according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.6 ALDOA LPP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.6 ALDOA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.6 ALDOA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.6 ALDOA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.6 LPP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.6 ALDOA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.6 ALDOA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.6 ALDOA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.6 LPP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.6 ALDOA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.6 ALDOA LPP
12 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.6 LPP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.6 LPP
14 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.6 LPP
15 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 ALDOA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.6 LPP
17 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.6 LPP

Drugs & Therapeutics for Prostate Carcinoma in Situ

Drugs for Prostate Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Toremifene Approved, Investigational Phase 3,Phase 2 89778-26-7 3005573
2
Selenium Approved, Vet_approved Phase 3 7782-49-2
3
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
4
Tamoxifen Approved Phase 3 10540-29-1 2733526
5 Tocopherol Approved, Nutraceutical Phase 3
6
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
7
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
8
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
10 Antineoplastic Agents, Hormonal Phase 3,Phase 2
11 Bone Density Conservation Agents Phase 3,Phase 2
12 Estrogen Receptor Modulators Phase 3
13 Estrogens Phase 3
14 Hormone Antagonists Phase 3,Phase 2,Phase 1
15 Hormones Phase 3,Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
17 Selective Estrogen Receptor Modulators Phase 3
18 Antioxidants Phase 3,Phase 2,Phase 1
19 Micronutrients Phase 3,Phase 2,Phase 1
20 Protective Agents Phase 3,Phase 2,Phase 1
21 Trace Elements Phase 3,Phase 2,Phase 1
22 Tocopherols Phase 3
23 Tocotrienols Phase 3
24 Vitamins Phase 3,Phase 2
25 11-hydroxyprogesterone Phase 3
26 17-alpha-hydroxy-progesterone caproate Phase 3
27 Ergocalciferols Phase 3
28 Progestins Phase 3
29 Estrogen Antagonists Phase 3
30 Citrate Nutraceutical Phase 3
31
Citric Acid Nutraceutical, Vet_approved Phase 3 77-92-9 311
32 Soy Bean Nutraceutical Phase 3
33 Tocotrienol Investigational, Nutraceutical Phase 3 6829-55-6
34 Calciferol Nutraceutical Phase 3
35 Vitamin D2 Nutraceutical Phase 3
36
Flutamide Approved Phase 2 13311-84-7 3397
37
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
38
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 6013
39
Lycopene Approved, Nutraceutical Phase 2,Phase 1 502-65-8 446925
40
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 134070 5280453
41
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
42
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
43 Androgen Antagonists Phase 2
44 Androgens Phase 2,Phase 1
45 Vaccines Phase 1, Phase 2
46 Carotenoids Phase 2,Phase 1
47 Radiation-Protective Agents Phase 2,Phase 1
48 Acyclovir Phase 1, Phase 2
49 Anti-Bacterial Agents Phase 1, Phase 2
50 Antibiotics, Antitubercular Phase 1, Phase 2

Interventional clinical trials:

(show all 32)

id Name Status NCT ID Phase Drugs
1 Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) Completed NCT00106691 Phase 3 Toremifene 20 mg;Placebo
2 S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate Completed NCT00030901 Phase 3 L-selenomethionine;L-selenomethionine placebo
3 Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia Completed NCT00064194 Phase 3
4 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
5 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
6 A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN) Completed NCT00028353 Phase 2 GTX-006 (Acapodene)
7 Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate Completed NCT00006214 Phase 2 flutamide
8 In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation Completed NCT00861107 Phase 1, Phase 2
9 The Effects of Lycopene on High Risk Prostatic Tissue Completed NCT01443026 Phase 2 Lycopene 30mg;Placebo
10 Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer Recruiting NCT01931046 Phase 1, Phase 2 Ad5-SGE-REIC/Dkk3
11 HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer Recruiting NCT01913106 Phase 1, Phase 2 HSV-tk +Valacyclovir in Combination with Brachytherapy
12 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
13 A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Active, not recruiting NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
14 Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia Active, not recruiting NCT00596011 Phase 2 Polyphenon E;Placebo
15 ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance Not yet recruiting NCT02721979 Phase 2 Apalutamide
16 Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia Terminated NCT00118066 Phase 2
17 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer Withdrawn NCT01065441 Phase 1, Phase 2
18 Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer Completed NCT00403221 Phase 1
19 Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II Completed NCT00250224 Phase 1
20 A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia Completed NCT00178113 Phase 1 - Lyc-O-Mato (dietary supplement, 30 mg lycopene/day);- Certagen (multivitamins with minerals)
21 Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy Recruiting NCT00788307 Phase 1 liothyronine sodium
22 Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer Recruiting NCT03262103 Phase 1
23 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
24 Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer Terminated NCT00005067 Phase 1 motexafin lutetium;photodynamic therapy
25 Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer Withdrawn NCT01197209 Phase 1
26 Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma Unknown status NCT00400894
27 The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study Unknown status NCT01842750
28 Broccoli, Peas and PIN Completed NCT00535977
29 Proteases in Patients With Prostate Cancer That Has Spread to the Bone Completed NCT00899665
30 Cancer Diagnosis by Multiparametric UltraSound of the Prostate Recruiting NCT02712684
31 Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer Terminated NCT02307552
32 FSH-R : Diagnostic Application for Localized Tumors in Cancerology Terminated NCT02860481

Search NIH Clinical Center for Prostate Carcinoma in Situ

Genetic Tests for Prostate Carcinoma in Situ

Anatomical Context for Prostate Carcinoma in Situ

MalaCards organs/tissues related to Prostate Carcinoma in Situ:

39
Prostate, Breast, Bone

Publications for Prostate Carcinoma in Situ

Variations for Prostate Carcinoma in Situ

Expression for Prostate Carcinoma in Situ

Search GEO for disease gene expression data for Prostate Carcinoma in Situ.

Pathways for Prostate Carcinoma in Situ

GO Terms for Prostate Carcinoma in Situ

Sources for Prostate Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....